NDAIMPLANTATIONIMPLANT
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
SINUVA (mometasone furoate) by PharmaIN is corticosteroids, mometasone furoate has anti-inflammatory, antipruritic, and vasoconstrictive properties. Approved for chronic rhinosinusitis with nasal polyps, nasal polyps. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SINUVA is a mometasone furoate implant approved in 2017 for chronic rhinosinusitis with nasal polyps. It delivers localized corticosteroid therapy via an in-situ forming implant to reduce inflammation and inhibit inflammatory mediators like prostaglandins and leukotrienes. This innovative implant modality differentiates it from oral or spray formulations of the same active ingredient.
Peak8.6 years to LOE
SINUVA is at peak commercial maturity with established market presence; careers on this brand focus on sustaining market share against emerging biologics rather than growth expansion.
Mechanism of Action
corticosteroids, mometasone furoate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory…
Indications (2)
Worked on SINUVA at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.